JP2015524917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524917A5 JP2015524917A5 JP2015516236A JP2015516236A JP2015524917A5 JP 2015524917 A5 JP2015524917 A5 JP 2015524917A5 JP 2015516236 A JP2015516236 A JP 2015516236A JP 2015516236 A JP2015516236 A JP 2015516236A JP 2015524917 A5 JP2015524917 A5 JP 2015524917A5
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- risk
- glyca
- nmr
- lipoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010012601 diabetes mellitus Diseases 0.000 claims 21
- 238000005481 NMR spectroscopy Methods 0.000 claims 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 18
- 239000008103 glucose Substances 0.000 claims 18
- 102000004895 Lipoproteins Human genes 0.000 claims 17
- 108090001030 Lipoproteins Proteins 0.000 claims 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 17
- 239000012472 biological sample Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 16
- 238000013178 mathematical model Methods 0.000 claims 14
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 13
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 13
- 150000005693 branched-chain amino acids Chemical class 0.000 claims 13
- 238000005259 measurement Methods 0.000 claims 13
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims 13
- 239000002245 particle Substances 0.000 claims 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 8
- 239000004474 valine Substances 0.000 claims 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 7
- 108010062497 VLDL Lipoproteins Proteins 0.000 claims 7
- 238000004891 communication Methods 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 5
- 230000003993 interaction Effects 0.000 claims 4
- 238000004590 computer program Methods 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 108010004103 Chylomicrons Proteins 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 235000020925 non fasting Nutrition 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 238000013517 stratification Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657315P | 2012-06-08 | 2012-06-08 | |
| US61/657,315 | 2012-06-08 | ||
| US201261711471P | 2012-10-09 | 2012-10-09 | |
| US61/711,471 | 2012-10-09 | ||
| US201261739305P | 2012-12-19 | 2012-12-19 | |
| US61/739,305 | 2012-12-19 | ||
| US13/830,784 US9361429B2 (en) | 2012-06-08 | 2013-03-14 | Multi-parameter diabetes risk evaluations |
| US13/830,784 | 2013-03-14 | ||
| PCT/US2013/044679 WO2013185014A1 (en) | 2012-06-08 | 2013-06-07 | Multi-parameter diabetes risk evaluations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018224690A Division JP6730410B2 (ja) | 2012-06-08 | 2018-11-30 | マルチパラメータ糖尿病リスク評価 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524917A JP2015524917A (ja) | 2015-08-27 |
| JP2015524917A5 true JP2015524917A5 (enExample) | 2016-06-16 |
| JP6522499B2 JP6522499B2 (ja) | 2019-05-29 |
Family
ID=49712667
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516236A Active JP6522499B2 (ja) | 2012-06-08 | 2013-06-07 | マルチパラメータ糖尿病リスク評価 |
| JP2018224690A Active JP6730410B2 (ja) | 2012-06-08 | 2018-11-30 | マルチパラメータ糖尿病リスク評価 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018224690A Active JP6730410B2 (ja) | 2012-06-08 | 2018-11-30 | マルチパラメータ糖尿病リスク評価 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9361429B2 (enExample) |
| EP (3) | EP2859337B1 (enExample) |
| JP (2) | JP6522499B2 (enExample) |
| CN (1) | CN104520699B (enExample) |
| AU (1) | AU2013271432B2 (enExample) |
| CA (1) | CA2875201C (enExample) |
| SG (1) | SG11201408002TA (enExample) |
| WO (1) | WO2013185014A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9470771B2 (en) | 2012-06-08 | 2016-10-18 | Liposcience, Inc. | NMR measurements of NMR biomarker GlycA |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US9361429B2 (en) * | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| KR102362357B1 (ko) * | 2013-04-09 | 2022-02-15 | 아지노모토 가부시키가이샤 | 생활습관병 지표의 평가 방법, 생활습관병 지표 평가 장치, 생활습관병 지표 평가 방법, 생활습관병 지표 평가 프로그램, 생활습관병 지표 평가 시스템, 및 정보통신 단말장치 |
| EP3058369B1 (en) * | 2014-01-06 | 2020-06-17 | Liposcience, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US10453562B2 (en) * | 2014-05-08 | 2019-10-22 | ProductVisionaries, LLC | Consumer-oriented biometrics data management and analysis system |
| US10261146B2 (en) | 2014-05-21 | 2019-04-16 | Aspect Imaging Ltd. | Unipolar fast spin echo for permanent magnet MRI |
| US10890636B2 (en) * | 2014-05-21 | 2021-01-12 | Aspect Imaging Ltd. | Diagnostic tool for EM perturbations in MRI systems |
| US20170103190A1 (en) * | 2015-10-09 | 2017-04-13 | Algorithm Inc | System and method for evaluating risks of clinical trial conducting sites |
| US10139461B2 (en) | 2016-06-14 | 2018-11-27 | Aspect Imaging Ltd. | Analysis of nuclear magnetic resonance spectra with non-stationary peaks |
| US9899038B2 (en) | 2016-06-30 | 2018-02-20 | Karen Elaine Khaleghi | Electronic notebook system |
| US11105875B2 (en) | 2016-09-12 | 2021-08-31 | Aspect Imaging Ltd. | Simultaneously frequency- and phase-shifted NMR signals and improved NMR signal analysis |
| DE102016224691A1 (de) * | 2016-12-12 | 2018-06-14 | Numares Ag | Verfahren zur Analyse eines NMR-Spektrums einer lipoproteinhaltigen Probe |
| CN108415917B (zh) * | 2017-03-13 | 2021-01-15 | 平安科技（深圳）有限公司 | 一种可视化报表的生成方法及可视化报表的生成装置 |
| US20190005201A1 (en) * | 2017-07-01 | 2019-01-03 | International Business Machines Corporation | Cognitive diabetic regulator |
| FI20177098A1 (fi) * | 2017-08-29 | 2019-03-01 | Leppaeluoto Juhani | Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen |
| WO2019051226A1 (en) | 2017-09-07 | 2019-03-14 | Liposcience, Inc. | METABOLIC VULNERABILITY INDEX ASSESSMENTS WITH MULTIPLE PARAMETERS |
| US10235998B1 (en) | 2018-02-28 | 2019-03-19 | Karen Elaine Khaleghi | Health monitoring system and appliance |
| US12093790B1 (en) | 2018-05-04 | 2024-09-17 | Massachusetts Mutual Life Insurance Company | Systems and methods for computational risk scoring based upon machine learning |
| CN109192318A (zh) * | 2018-07-11 | 2019-01-11 | 辽宁石油化工大学 | 描述传染病传播过程的简化SIS模型的建立与Laplace分析 |
| JP7621937B2 (ja) * | 2018-09-14 | 2025-01-27 | １０２５０９２９ カナダ インコーポレーテッド | 代謝産物レベルのｉｎ－ｖｉｖｏ非侵襲的測定のための方法及びシステム |
| US10559307B1 (en) | 2019-02-13 | 2020-02-11 | Karen Elaine Khaleghi | Impaired operator detection and interlock apparatus |
| US10735191B1 (en) | 2019-07-25 | 2020-08-04 | The Notebook, Llc | Apparatus and methods for secure distributed communications and data access |
| CN112903885B (zh) * | 2019-12-03 | 2022-05-06 | 中国科学院大连化学物理研究所 | 一种筛查糖尿病的联合型代谢标志物的应用及其试剂盒 |
| FI130424B (en) * | 2020-06-18 | 2023-08-23 | Nightingale Health Oy | Procedure for determining whether a subject has a disease or condition or whether the subject is at risk of developing a disease or condition |
| EP4281768A1 (en) * | 2021-01-22 | 2023-11-29 | Bruker BioSpin MRI GmbH | Infection diagnosis and characterization using diffusion and relaxation edited proton nmr spectroscopy |
| US20240044826A1 (en) | 2022-08-05 | 2024-02-08 | Liposcience, Inc. | Metabolic vulnerability analyzed by nmr |
| EP4581355A1 (en) * | 2022-08-31 | 2025-07-09 | Laboratory Corporation of America Holdings | Methods and systems for measuring citrate and creatinine levels by nmr spectroscopy |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529710A (en) | 1981-06-12 | 1985-07-16 | The United States Of America As Represented By The United States Department Of Energy | Method of using a nuclear magnetic resonance spectroscopy standard |
| JPH0698036B2 (ja) | 1986-10-20 | 1994-12-07 | 小野薬品工業株式会社 | アミノ酸の選択的定量法 |
| US4933844A (en) | 1988-09-26 | 1990-06-12 | Otvos James D | Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer |
| US6653140B2 (en) * | 1999-02-26 | 2003-11-25 | Liposcience, Inc. | Methods for providing personalized lipoprotein-based risk assessments |
| WO2000051054A1 (en) | 1999-02-26 | 2000-08-31 | Lipomed, Inc. | Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood |
| CA2367820C (en) * | 1999-04-22 | 2009-12-22 | James D. Otvos | Nmr-method for determining the risk of developing type 2 diabetes |
| US7329489B2 (en) | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| CA2331116A1 (en) | 2001-01-15 | 2002-07-15 | Chenomx, Inc. | Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system |
| WO2003012416A1 (en) | 2001-08-01 | 2003-02-13 | Liposcience, Inc. | Method of determining presence and concentration of lipoprotein x in blood plasma and serum |
| WO2003107270A2 (en) | 2002-06-14 | 2003-12-24 | Pfizer Limited | Metabolic phenotyping |
| US7243030B2 (en) | 2002-10-25 | 2007-07-10 | Liposcience, Inc. | Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals |
| WO2004085996A2 (en) | 2003-03-20 | 2004-10-07 | Albert Einstein College Of Medicine Of Yeshiva University | Biomarkers for longevity and disease and uses thereof |
| US9062306B2 (en) | 2003-04-29 | 2015-06-23 | Biocrine Ab | Methods for identifying compounds for treating type 1 diabetes |
| CA2542107A1 (en) | 2003-10-23 | 2005-05-12 | Liposcience, Inc. | Methods, systems and computer programs for assessing chd risk using mathematical models that consider in vivo concentration gradients of ldl particle subclasses of discrete size |
| AU2005230449B2 (en) | 2004-04-01 | 2010-02-18 | Liposcience, Inc. | NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples |
| DE102004026903B4 (de) | 2004-06-01 | 2006-05-18 | Universität Regensburg | Verfahren zur Bestimmung von Lipoproteinen in Körperflüssigkeiten und Messanordnung dafür |
| WO2006057081A1 (en) | 2004-11-24 | 2006-06-01 | Mitsuyo Okazaki | Method for analyzing lipoproteins |
| US7629315B2 (en) * | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| US7373256B2 (en) | 2005-04-19 | 2008-05-13 | Nicholson Jeremy K | Method for the identification of molecules and biomarkers using chemical, biochemical and biological data |
| JP5006524B2 (ja) | 2005-05-13 | 2012-08-22 | 株式会社日立製作所 | 緩和時間特定のためのｎｍｒ装置の信号処理方法 |
| US8119358B2 (en) | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| US7972802B2 (en) | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
| JP4358814B2 (ja) | 2005-11-09 | 2009-11-04 | 花王株式会社 | 試料の解析方法 |
| DE602007011592D1 (de) * | 2006-03-24 | 2011-02-10 | Metanomics Gmbh | MITTEL UND VERFAHREN ZUR PROGNOSE ODER DIAGNOSE VON DIABETES typ II |
| WO2007133593A2 (en) | 2006-05-10 | 2007-11-22 | Liposcience, Inc. | Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements |
| US20080026378A1 (en) | 2006-07-28 | 2008-01-31 | Gian Franco Bottazzo | Prediction and prophylactic treatment of type 1 diabetes |
| US20080300170A1 (en) | 2006-09-01 | 2008-12-04 | Cohava Gelber | Compositions and methods for diagnosis and treatment for type 2 diabetes |
| WO2008137075A2 (en) | 2007-05-02 | 2008-11-13 | President And Fellows Of Harvard College | Compositions and methods for the treatment of metabolic disorders and inflammation |
| US7923257B2 (en) | 2007-05-04 | 2011-04-12 | Perkinelmer Health Sciences, Inc. | Detecting isomers using differential derivatization mass spectrometry |
| BRPI0815095B1 (pt) | 2007-07-17 | 2021-04-13 | Metabolon, Inc | Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo |
| EP2019311A1 (en) | 2007-07-23 | 2009-01-28 | F.Hoffmann-La Roche Ag | A method for detecting a target substance by nuclear magnetic resonance |
| US7923253B2 (en) | 2007-11-05 | 2011-04-12 | Battelle Memorial Institute | Method for identifying type I diabetes mellitus in humans |
| US8673644B2 (en) | 2008-05-13 | 2014-03-18 | Battelle Memorial Institute | Serum markers for type II diabetes mellitus |
| WO2010005982A2 (en) | 2008-07-07 | 2010-01-14 | The General Hospital Corporation | Multiplexed biomarkers of insulin resistance |
| WO2010011860A1 (en) | 2008-07-23 | 2010-01-28 | Diabetomics, Llc | Methods for detecting pre-diabetes and diabetes |
| EP2344890B1 (en) | 2008-10-20 | 2021-08-11 | Liposcience, Inc. | Lipoprotein insulin resistance indexes and related methods |
| WO2010114897A1 (en) * | 2009-03-31 | 2010-10-07 | Metabolon, Inc. | Biomarkers related to insulin resistance and methods using the same |
| EP2270530B1 (en) | 2009-07-01 | 2013-05-01 | Københavns Universitet | Method for prediction of lipoprotein content from NMR data |
| US7935643B2 (en) | 2009-08-06 | 2011-05-03 | Applied Materials, Inc. | Stress management for tensile films |
| US8741788B2 (en) | 2009-08-06 | 2014-06-03 | Applied Materials, Inc. | Formation of silicon oxide using non-carbon flowable CVD processes |
| US8367359B1 (en) | 2009-10-23 | 2013-02-05 | The United States Of America, As Represented By The Secretary Of Agriculture | Metabolic biomarkers for diabetes and insulin resistance |
| JP2013509587A (ja) | 2009-10-29 | 2013-03-14 | テシス バイオサイエンス， インコーポレイテッド | 糖尿病のリスクを決定する方法 |
| JP2013509588A (ja) | 2009-10-29 | 2013-03-14 | テシス バイオサイエンス， インコーポレイテッド | ２型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー |
| US8449942B2 (en) | 2009-11-12 | 2013-05-28 | Applied Materials, Inc. | Methods of curing non-carbon flowable CVD films |
| US20110136241A1 (en) * | 2009-12-08 | 2011-06-09 | Stephen Naylor | Type ii diabetes molecular bioprofile and method and system of using the same |
| CN102754193A (zh) | 2010-01-06 | 2012-10-24 | 应用材料公司 | 使用氧化物衬垫的可流动电介质 |
| CA2799757C (en) | 2010-05-21 | 2018-12-04 | The Governors Of The University Of Alberta | Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine |
| WO2011153271A1 (en) | 2010-06-01 | 2011-12-08 | Boston Heart Lab | Predicting plaque composition and phenotype in coronary arteries via hdl-subclass analysis, and methods related thereto |
| EP3151012B1 (en) | 2010-09-21 | 2018-03-21 | Proteomics International Pty Ltd | Biomarkers associated with diabetic nephropathy |
| DE102010038014B4 (de) | 2010-10-06 | 2021-10-07 | Numares Ag | Verwendung spezifischer Substanzen als Marker zur Bestimmung des Risikos einer Nierenabstoßung |
| US9404178B2 (en) | 2011-07-15 | 2016-08-02 | Applied Materials, Inc. | Surface treatment and deposition for reduced outgassing |
| US9361429B2 (en) | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US9470771B2 (en) | 2012-06-08 | 2016-10-18 | Liposcience, Inc. | NMR measurements of NMR biomarker GlycA |
| CA2887475C (en) | 2012-10-09 | 2021-12-14 | Liposcience, Inc. | Nmr quantification of branched chain amino acids |
| EP3058369B1 (en) | 2014-01-06 | 2020-06-17 | Liposcience, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
-
2013
- 2013-03-14 US US13/830,784 patent/US9361429B2/en active Active
- 2013-06-07 EP EP13800325.6A patent/EP2859337B1/en active Active
- 2013-06-07 SG SG11201408002TA patent/SG11201408002TA/en unknown
- 2013-06-07 AU AU2013271432A patent/AU2013271432B2/en active Active
- 2013-06-07 EP EP20189171.0A patent/EP3822651B1/en active Active
- 2013-06-07 WO PCT/US2013/044679 patent/WO2013185014A1/en not_active Ceased
- 2013-06-07 JP JP2015516236A patent/JP6522499B2/ja active Active
- 2013-06-07 CA CA2875201A patent/CA2875201C/en active Active
- 2013-06-07 US US14/405,852 patent/US9792410B2/en active Active
- 2013-06-07 CN CN201380041864.1A patent/CN104520699B/zh active Active
- 2013-06-07 EP EP23209933.3A patent/EP4365913A3/en active Pending
-
2016
- 2016-05-03 US US15/145,409 patent/US10388414B2/en active Active
-
2018
- 2018-11-30 JP JP2018224690A patent/JP6730410B2/ja active Active
-
2019
- 2019-07-02 US US16/460,269 patent/US11710568B2/en active Active
-
2023
- 2023-06-16 US US18/210,959 patent/US20240096497A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524917A5 (enExample) | ||
| Selby et al. | Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA | |
| JP6730410B2 (ja) | マルチパラメータ糖尿病リスク評価 | |
| Rogers et al. | Standardization of T1 measurements with MOLLI in differentiation between health and disease–the ConSept study | |
| JP2015522806A5 (enExample) | ||
| Williams et al. | Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes | |
| Holmes et al. | Analytical variability among methods for the measurement of 25-hydroxyvitamin D: still adding to the noise | |
| Da Costa et al. | The association between obesity, cardiometabolic disease biomarkers, and innate immunity-related inflammation in Canadian adults | |
| Mao et al. | Association between homocysteine status and the risk of nephropathy in type 2 diabetes mellitus | |
| Robinson et al. | Validation of an enzyme-linked immunoassay (ELISA) for plasma oxytocin in a novel mammal species reveals potential errors induced by sampling procedure | |
| JP7439009B2 (ja) | Ｈｄｌおよび炎症性バイオマーカインタラクションパラメータを含むリスクパラメータを用いた心血管リスク評価 | |
| Reeder | Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis | |
| KR20110086074A (ko) | 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램 | |
| Wang et al. | Characterization of human plasma proteome dynamics using deuterium oxide | |
| JP6268181B2 (ja) | 分岐鎖状アミノ酸のｎｍｒ定量 | |
| Murray et al. | The influence of measurement location on reliability of quantitative nailfold videocapillaroscopy in patients with SSc | |
| Tate et al. | Opinion paper: deriving harmonised reference intervals–global activities | |
| Liu et al. | Adult obesity diagnostic tool: a narrative review | |
| Radišić Biljak et al. | Laboratory diagnostics of chronic kidney disease in Croatia: state of the art | |
| Raff | Measurement of salivary cortisone to assess the adequacy of hydrocortisone replacement | |
| Çubukçu et al. | Uncertainty of measurement for 14 immunoassay analytes: application to laboratory result interpretation | |
| Hughes et al. | Abnormalities of selenium but not of copper homeostasis may drive tissue fibrosis in patients with systemic sclerosis | |
| CN112305246A (zh) | 样本分析方法及样本分析系统 | |
| DeVan et al. | To what extent are free testosterone (FT) values reproducible between the two Washingtons, and can calculated FT be used in lieu of expensive direct measurements? | |
| Mathur et al. | Is point of care renal function testing reliable screening pre-IV contrast administration? |